Humacyte Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Humacyte Inc.
- Former names
- Alpha Healthcare Acquisition Corp.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Durham
- Headquarters state / province
- North Carolina
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- HUMA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001818382
- EIN
- 85-1763759
Board of directors
-
Brady W. Dougan · DirectorSince 2023
-
Charles Bruce Green · DirectorSince 2023
-
D. Scott Coward · DirectorSince 2026
-
Diane Seimetz · DirectorSince 2023
-
Emery N. Brown · DirectorSince 2023
-
Gordon M. Binder · DirectorSince 2023
-
John Philip Bamforth · DirectorSince 2024
-
Kathleen Sebelius · DirectorSince 2023
-
Keith Anthony Jones · DirectorSince 2024
-
Laura E. Niklason · Director · President, CEO and DirectorSince 2023
-
Max N. Wallace · DirectorSince 2023
-
Michael T. Constantino · DirectorSince 2023
-
Paul Brian Kuznik · DirectorSince 2026
-
Rajiv Shukla · DirectorSince 2023
-
Susan Richards Windham-Bannister · DirectorSince 2023
-
Todd Pope · DirectorSince 2023
Chief executives
Laura E. Niklason
· President, CEO and Director
Dates unknown
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
77.6%
-
84.7%
-
84.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $90,160
- 5 purchases by 3 insiders
- Sold, last 12 months
- $82,597
- 2 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 14, 2026 | Keith Anthony Jones Director | Open-market purchase | +10,000 | $0.56 | $5,620 |
| Aug 20, 2026 | Keith Anthony Jones Director | Open-market purchase | +10,000 | $0.69 | $6,930 |
| Aug 17, 2026 | Keith Anthony Jones Director | Open-market purchase | +30,000 | $0.59 | $17,820 |
| May 19, 2026 | Kathleen Sebelius Director | Open-market purchase | +56,818 | $0.88 | $50,000 |
| May 18, 2026 | Michael T. Constantino Director | Open-market purchase | +11,000 | $0.89 | $9,790 |
| May 18, 2026 | Sander Dale A. Officer (CFO and Chief Corp. Dev. Off) | Open-market sale | −45,887 | $0.90 | $41,298 |
| May 18, 2026 | Parikh Shamik J Officer (Chief Medical Officer) | Open-market sale | −45,887 | $0.90 | $41,298 |
| Nov 16, 2025 | Sander Dale A. Officer (CFO and Chief Corp. Deve. Off.) | Grant or award | +311,100 | — | — |
| Nov 16, 2025 | Parikh Shamik J Officer (Chief Medical Officer) | Grant or award | +311,100 | — | — |
| Aug 20, 2025 | Brady W. Dougan Director | Open-market sale | −591,685 | $1.58 | $934,862 |
| Aug 20, 2025 | Laura E. Niklason Director, Officer (President, CEO and Director) | Open-market sale | −591,685 | $1.58 | $934,862 |
| Aug 19, 2025 | Brady W. Dougan Director | Open-market sale | −1,100,000 | $1.63 | $1,793,000 |
| Aug 19, 2025 | Laura E. Niklason Director, Officer (President, CEO and Director) | Open-market sale | −1,100,000 | $1.63 | $1,793,000 |
| Aug 18, 2025 | Brady W. Dougan Director | Open-market sale | −549,360 | $1.83 | $1,005,329 |
| Aug 18, 2025 | Laura E. Niklason Director, Officer (President, CEO and Director) | Open-market sale | −549,360 | $1.83 | $1,005,329 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.